Pesquisar um ensaio clínico
Outras opções de pesquisa
10 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
PAISES BAIXOS
Noord-Holland
AMSTERDAM
Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations (Phase III) - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638 - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
BALANCE: A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta (Phase III) - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) (Phase III) - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM
MODIFY: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine the EffIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (Phase III) - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
PAISES BAIXOS
Noord-Holland
AMSTERDAM